Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PM in defense of Northwest
Its since two years a trend to pump and dump pre-topline data biotechs with the following setup:
they hype before the biotech announces topline data
everybody buys in knowing/expecting trial results will be awesome.
SP rises in anticipation of TLD. Shorts take a short position before the TLD announcement
No one wants to buy AFTER the announcement of TLD, all retailers expect the SP to explode after topline data has been announced.
TLD is announced and is as expected good-great
Shorts start to sowing doubt and sell more, no volume to pick up the selling volume cause all retailers have already bought all they can handle.
Panic starts everyone is selling stop losses are broken, and short cover at lower prices.
Northwest is not the first who has been subject to this, it has happened many many times with other biotechs over the last 2 years. The days of Dendreon x5 SP after topline data are far behind us.
exactly well said
IF they attempt to increase the A/S without any business case/substantial progress they will NEVER get the needed 50% of 1,032,974,769 shares is 515 million shares to vote yes. Everyone voting no and absence of voting is counted as a NO
IF they would attempt a vote on increasing A/S without anything to show for it will crash the SP further with ? 50%. Are they that stupid trying such vote... asking it is answering it
is that so, Im not sure this seems to be the first time he said this:
We are still constrained by the efforts of getting manuscript published.
and especially this
when we have gotten the nod for a journal publication, we will let everyone know
I could be wrong here
NO not notice by June 18th meeting before or ON June 18th
You are incorrectly reading the law stipulating this
why would I want to send an email to the producers of the website https://delcode.delaware.gov/title8/c001/sc07/index.html
I have NO problem with https://delcode.delaware.gov/title8/c001/sc07/index.html website
You disagree with this line
the Court of Chancery may summarily order a meeting to be held upon the application of any stockholder or director
so you can email the website for them to remove that text.
Have a good one hoffy
hey if they arranged a BO or JV and that's the reason for the ASM delay then I will publicly apologize lol
But that's not the case. The reason is most likely that they dont dare to show themselves to shareholders without PRing the TLD and they cant until the JA. At the ASM most likely the A/S will be increased which is IMpossible without PRed TLD and JA.
Btw I think its impossible to have the A/S increased WITH JA+PRed TLD as well
Hoffy I said that if you do not agree https://delcode.delaware.gov/title8/c001/sc07/index.html about
https://delcode.delaware.gov/title8/c001/sc07/index.html
then by all means email whomever produced the website https://delcode.delaware.gov/title8/c001/sc07/index.html
who on earth could you have twisted that what I just said in "An email is not sufficient." ?
this
the Court of Chancery may summarily order a meeting to be held upon the application of any stockholder or director
is hoffy?
Ok then by all means email https://delcode.delaware.gov/title8/c001/sc07/index.html
that they have it wrong
well what is toothless define toothless. What a humiliation it must be for Linda Powers if the Court of Chancery would summarily order a meeting to be held. And in this case, I am pretty sure the court would actually summon such a meeting no matter what Northwest would say, all it takes is one shareholder complaining, and applying. So not that toothless. Toothless would mean absolutely nothing happens, this is not absolutely nothing.
Tbh right now I am hoping a shareholder would write with the Court of Chancery and complaints
not a recommendation law
https://delcode.delaware.gov/title8/c001/sc07/index.html
If there be a failure to hold the annual meeting or to take action by written consent to elect directors in lieu of an annual meeting for a period of 30 days after the date designated for the annual meeting, or if no date has been designated, for a period of 13 months after the latest to occur of the organization of the corporation, its last annual meeting or the last action by written consent to elect directors in lieu of an annual meeting, the Court of Chancery may summarily order a meeting to be held upon the application of any stockholder or director.
100% agree
and saying they have not released topline data is a silly argument
Top-Line Data means, with respect to a Clinical Trial, a summary of demographic data, the data for the primary endpoint(s), the data for any secondary endpoint(s), if such secondary endpoint(s) are applicable, and a summary of safety data, in each case which are based on an unblinded, locked database and wherein all data are collected in a 21 CFR 11 validated database with a complete audit trail.
Talks about Covid and still no Topline PR /JA. Seems we are stuck in a never-ending time loophole. Lol
well substantial sales would only be believed by the market if marketing approval is near, so the submission for approval would set the SP above 2 billion in market cap
for this would generate substantial sales within a year or sooner after approval.
a JV for a large amount would increase MC substantially, for example, a JV with Merck. Or a royalties deal with Merck for the right to sell DCVAX L.
What Im expecting realistically after JA is more dilution, unfortunately, and no such deal until the day of BO. We then in that case will only settle above 2$ for good after marketing approval. I hope Im wrong and they have arranged something more original than printing more shares. And if they will be printing shares then hopefully they will sell 10% in NWBO against $7 a share to Merck after JA.
But Im probably dreaming.
Northwest needs a royalties deal a money influx a clear path to revenue in the short term an investment you name it as long as it is a big pile of cash in, and then it will run. That's how biotech stocks work nowadays.
Thank you for sharing.
There is not one reason I have read or can think of why Northwest has not submitted for the approval of DCVAX L together with the request for approval of commercial production for Advent. Not one. There is absolutely no reason to wait for the approval for the commercial production of DCVAX L has to come in first before they can submit a request to approve DCVAX L.
There must be another reason why they didnt submit a request for approval of DCVAX L with the MHRA. Im disappointed and shocked they have not so far requested any form of approval with any RA, 22 months after data lock.
It would not surprise me if Northwest holds some sort of all-time record among all biotechs ever for not submitting a request approval so many months after data lock on overwhelming good data.
Thank you PQR,
I dont have PM :)
What I think has happened is that Northwest (their lawyers) felt compelled to contradict the hardened rumors on message boards and social media about a fast upcoming MHRA approval and the many times they have been asked about the MHRA pending approval. Not to say the least because it was LG himself who in Oct 2020 in the Big Booz show claimed that MHRA approval is imment.
So although I do think that Northwest has prepared the submission of the request for approval, I don't think they have submitted anything yet. I think they are waiting for approval of the manufacturing license for commercial production of cellular products in the Sawston facility by year-end and THEN submit a request for the approval for DCVAX L. This is for the simple reason that Northwest wants to make sure an approval will not be declined based on the pending capacity of production of DCVAX-L. This will thus take us to Q1 2023 for MHRA approval of DCVAXL just like SOS predicted.
If we are not going to be diluted like cheap soup then I expect the SP to rise in anticipation of MHRA approval over the course of the next 9 months to $5-6$
IMO :)
This to me is very disappointing
Such a manufacturing license is separate from any regulatory decision about approval of DCVax-L itself. The Company has not to date submitted an application for commercial approval of DCVax-L.
NWBO was at $1066 (check chart at Yahoo) 20 years ago, now is at 63 cents.
AMZN was at 30 cents on July 2001, now is at $110
You forgot to mention that 1 NWBO share then is 1/5 now and 1 Amazon then is 20 now. So its much worse
The number of shares, warrants and options NWBO insiders/management has been granted by the board are about 200 million shares if I'm correct. So if the A/S would be around 1.4 billion (1.2 now + these 200 million) then near 15% of the o/s are being held by NWBO insiders.
Some have suggested that if it comes to an increase in A/S that retail shareholders have no chance because large shareholders would win the vote anyway. That's incorrect. For an increase of A/S NWBO must have 526,817,132 shares to vote YES (1,032,974,769 from the outstanding shares x 51%) . Im pretty sure the top 10 biggest shareholders in NWBO will definitely NOT get to that count IF they all would vote YES.
If NWBO would put an increase of A/S on the table after the JA+TLD PR endpoints have been met and after a huge SP drop because they have put that proposal of increase of A/S on the agenda then Im sure many retail shareholders would, in that scenario, be discouraged and refrain from voting which is the same as voting NO.
For that reason, I can't imagine LP putting the increase of A/S on the table (if she seriously considers this) without something additional that would really increase the market cap of NWBO
There is some confusion here about what the difference is between the Stock shell and increase of authorized shelf. Definitions
Reading posts like that cant wait to sell at 4 and never look back
its a brilliant trap lol Reminds me of a Pink Panther movie
I advise you to really do some reading up, on how medical trials are being conducted. Your assumption already fails here:
actually, management has a huge influence on the timeline of the appearance of the JA. If they would not be so incredibly stubborn and choose to release the JA in JTM we would have seen the JA already many months ago. Aiming to publish the JA in conservative high-end journals such as NEJM/JAMA/Lancet/AOO perse is what has delayed the JA by many months. Publication of the JA in JTM would have not made any difference when it comes to the progress of the company and approval of DCVAX L.
The reason for this huge delay is EGO thats it
As per Vubru:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169153809